Aug 2026· Stem cell research & therapeutics· Vol 17· 0 citations· 40 references
Medicine
TL;DR
This integrated bone marrow organoid platform provides a physiologically relevant system for studying human hematopoietic development and immune cell differentiation and offers a scalable foundation for regenerative medicine and immunotherapy applications.
Abstract
The anatomical separation of bone marrow and thymus limits the efficient generation of human immune cells in vitro and constrains experimental platforms for modeling integrated hematopoiesis. We investigated whether a synthetic human bone marrow could be engineered to support both hematopoietic and T-lineage-associated functions. We generated human induced pluripotent stem cell-derived bone marrow organoids (iBMOs) that self-organize into stromal, vascular, and hematopoietic compartments and provide microenvironmental cues supportive of T cell differentiation. iBMOs produced hematopoietic progenitors and yielded stable stromal stem cell lines (iBOSS) that expressed Notch-associated molecules and supported the differentiation of iPSC-derived hematopoietic progenitors toward T-lineage and dendritic cell-associated populations in vitro. Following transplantation into immunodeficient mice, iBMOs sustained human erythropoiesis and underwent bone formation, demonstrating autonomous niche activity in vivo. This integrated bone marrow organoid platform provides a physiologically relevant system for studying human hematopoietic development and immune cell differentiation and offers a scalable foundation for regenerative medicine and immunotherapy applications.
A protocol to isolate and expand MSCs from human umbilical cord tissue and characterize their cell surface protein expression by flow cytometry, self-renewal potential by colony-forming assay, and tri-lineage differentiation capacity is outlined.
Yi-Xuan Dai, Avital Mendelson· Methods in molecular biology· 0 citations
The expansion of immunosuppressive myeloid cells drives tumor progression, yet clinical strategies aimed at depleting these populations have shown limited effects and high toxicity. Because myeloid cells arise from hematopoietic progenitors, we asked whether solid tumors durably reprogram hematopoietic stem and progeni...
Emily Eul, Giulia Furesi, Wen-Tao Han et al.· Blood· 0 citations
This chapter describes two in vitro assays designed to assess the hematopoietic stem/progenitor cell (HSPC)-supporting capacity of primed MSCs, and the other is specifically aimed at their ability to support the growth of primitive HSCs.
Vaijayanti Kale· Methods in molecular biology· 0 citations
Background/Objectives: Mesenchymal stromal cells (MSCs) isolated from neonatal sources have been proposed in clinical cell therapy to enhance hematopoietic stem cell transplantation due to their hematopoietic support capacity. Here we evaluated this capacity, particularly the lymphopoietic potential that remains poorly...
Ixel Luna-Cañedo, G. Fajardo-Orduña, R. Pelayo et al.· Biomedicines· 0 citations
This review summarizes research with a focus on clinical translation of iPSC-derived immune cells, as well as highlights continued challenges and prospects of this field.
Luisjesus S. Cruz, Alejandro R. Castañeda, Dan S. Kaufman· Stem Cells· 0 citations
Background Mesenchymal stem cells (MSCs) are multipotent, nonhematopoietic progenitors capable of supporting hematopoiesis and regulating immunity. Clinical studies have shown that MSCs can aid hematopoietic recovery and balance T helper 17 (Th17) and Treg cells in some aplastic anemia (AA) patients refractory to immun...